RMC No. 42-2023 — Publishes the February 21, 2023 letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Products under RA No. 10963 (TRAIN Law) and RA No. 11534 (CREATE Act) Digest | Full Text | Annex A

BUREAU OF INTERNAL REVENUE REPUBLIC OF THE PHILIPPINES DEPARTMENT OF FINANCE BUREAU OF INTERNAL ReVENUE NnYYTYN t1:5r pM APR 0 4 2023

RECORDS MGT.DIVISION TyGT

U.4 APR 2023

REVENUE MEMORANDUM CIRCULAR NO. 42- 20?3

SUBJECT : Publishing the Full Text of the February 21,2023 Letter from the Food and

Drug Administration (FDA) of the Department of HeaIth (DOH) Endorsing

No. 10963 (TRAIN Law) and R.A. No. 11534 (CREATE Act) Updates to the List of VAT-Exempt Products Under Republic Act (R.A.)

TO All Internal Revenue Officers and Others Concerned

concerned, attached is the February 21, 2023 letter (Annex "A) from Dr. Samuel A. Zacate, Director General of the FDA, for inclusion of certain medicines for cancer, diabetes, kidney disease, mental illness, and tuberculosis and correction for medicines for high cholesterol and For the information and guidance of all internal revenue officers, employees and others

CREATE Act. hypertension to the published List of VAT-Exempt Medicines Under R.A. No. 11534 or the

exemption of the covered medicines and medical devices under the CREATE Act shall be on As clarified under Q&A No. 1 of RMC No. 99-2021, the effectivity of the VAT

the date of publication by the FDA of the updates to the said list.

wide a publicity as possible. All concerned are hereby enjoined to be guided accordingly and give this Circular as

Commissioner of Internal Revenue ROMEO D. LUMAGUI, JR.

By HE0S MARISSA Deputly Cormissioner tegal U.cabreros 0124

Offiser-in-Charge R50 207-2023